Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel

Abstract

Cetuximab was safely associated with paclitaxel, obtaining a rapid tumor response in cisplatin-refractory metastatic cSCC. Single-agent cetuximab maintenance sustained tumor shrinkage until complete response.